HomeCLINICAL TRIALS, STUDIES, REGISTRIES, DATA

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

“The Decipher Prostate test’s ability to help guide treatment for patients with localized prostate cancer is already proven in dozens of peer-reviewed publications and is the only molecular test to achieve ‘Level 1B’ evidence status in the most recent NCCN® Guidelines* for prostate cancer,” said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. “These new phase 3 data from the STAMPEDE trial now further prove the performance and utility of our test in patients with metastatic prostate cancer. We believe our test can have a tremendous positive impact on care for these patients.”

Delcath Systems Reports Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

The 30-patient study reported that the Delcath Systems HEPZATO KIT™ (melphalan/Hepatic Delivery System (HDS)) provided better disease control in the liver and improved progression-free survival in patients with hepatic metastases from uveal melanoma, compared to both immunotherapy and other liver-directed therapies.

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

"This analytical validation study strongly complements EsoGuard's extensive peer-reviewed, published clinical validity and clinical utility evidence base," said Suman Verma, M.D., PhD, Chief Scientific Officer at Lucid Diagnostics. "The results demonstrate very robust analytical performance of the EsoGuard assay performed in our CLIA-certified, CAP-accredited, NY State-approved commercial laboratory."

Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

The funding will be used to support Jupiter Endovascular in their upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology.

osteolabs Publishes First Real-World Evidence Data from Close to 3, 000 OsteoTest Patient Samples

“We are very excited about the results from this collaborative effort that have now culminated in a publication in Bone, “ said Prof. Anton Eisenhauer who is a key inventor of the CIM technology and osteolabs´ Chief Scientific Officer. “This larger subset of routine clinical samples fully supports the potential for OsteoTest to qualify as a new universal diagnostic method for early osteoporosis risk assessment and therapeutic control.”

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Genprex notes the patients in the Company's lung cancer clinical trials are being treated with the Company's lead drug candidate, Reqorsa® (quaratusugene ozeplasmid) Gene Therapy. Two patients in the Acclaim-1 study have had prolonged Progression Free Survival (PFS) and importantly, the first treated patient in the Acclaim-3 study attained a Partial Remission (PR) from the start of maintenance therapy.

Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

The Hemopurifier Cancer Trial will be conducted by Dr. Marco Matos and his staff at the Pindara Private Hospital, located in Queensland, Australia.

New Studies Validate the Value of Brainomix AI Technology Across US Stroke Networks

The latest research, in collaboration with the Mayo Clinic, West Virginia University, and Boston Medical Center, highlighted some of the cutting-edge, AI-enabled technology that the Oxford-based company has developed within its pipeline for the Brainomix 360 Stroke platform, representing groundbreaking capabilities that will enable physicians to extract maximal value from universally available non-contrast CT scans across stroke networks.

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Patient enrollment in the RELIEVE UCCD (ulcerative colitis and Crohn’s disease) Phase 2b trial has completed early due to significant acceleration in patient recruitment. As a result, Teva Pharmaceuticals and Sanofi now anticipate having topline results for both UC and CD in Q4 2024, and detailed results will be presented in a scientific forum in 2025. This adjustment replaces the previously planned interim analysis for the second half of 2024, which will not be conducted. Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug for moderate-to-severe UC and CD patients.